Psilocybin: From Psychiatric Pariah to Perceived Panacea.

Area of Science:

• Psychopharmacology
• Clinical Psychology
• Neuroscience

Background:

• Psilocybin, a psychedelic compound, is being investigated for its therapeutic potential in psychiatric disorders.
• Psychological support/therapy (PST) is often administered alongside psilocybin to enhance treatment outcomes.

Purpose of the Study:

• To critically evaluate the existing evidence for psilocybin-assisted therapy (PST) in treating psychiatric conditions.
• To provide recommendations for future research in this emerging field.

Main Methods:

• A comprehensive literature search was conducted on PubMed for English-language articles published between January 1998 and November 2023, using the keyword "psilocybin."
• Screening of 1,449 articles identified 21 unique open-label or randomized controlled trials (RCTs) across various psychiatric disorders, including major depressive disorder (MDD), anxiety/depression, substance use disorders, and others.
• Analysis focused on the quality of evidence, study designs, and identified limitations.

Main Results:

• The most robust evidence exists for major depressive disorder (MDD), with three double-blind RCTs indicating positive outcomes.
• However, the validity of these findings is challenged by issues such as imperfect blinding, small sample sizes, variability in treatment protocols, limited participant diversity, and potential expectancy effects.
• Limited understanding of psilocybin's mechanisms of action and predictors of treatment response was noted.

Conclusions:

• Current evidence is insufficient to endorse psilocybin with PST as a standard psychiatric treatment.
• Further rigorously designed clinical trials are essential to confirm efficacy in larger, diverse populations, optimize dosing, improve study blinding, and elucidate mechanisms of action.
• Comparative studies against established treatments are needed to define the future role of psilocybin-assisted therapy.